Skip to main content
. 2020 Mar 12;46(4):599–611. doi: 10.1590/S1677-5538.IBJU.2019.0343

Table 6. Patients´ baseline characteristics of treated with 223Ra in the 3 lines of therapy.

223Ra therapy First line (11p) Concomitant (Abiraterone/Enzalutamide) (13p) Followed by other treatments (19p)

Baseline variable n n n
Age Mean 70 years 71 years 71 years
ECOG status 1 3 2 3
≥2 8 11 16
CPL 1-2 8 2 8
3 3 11 11
Bone metastases (Bone-Scan) 2-6 6 4 5
>6 5 7 10
Superscan 0 2 4
Hb (g/dL) <12.9 4 10 11
>13 7 3 8
PSA (ng/mL) <99.9 10 7 7
>100 1 6 12
ALP (U/L) <199.9 6 5 12
>200 5 8 7